Artivion (AORT) Expected to Announce Earnings on Thursday

Artivion (NYSE:AORT - Get Free Report) is expected to be releasing its earnings data after the market closes on Thursday, February 20th. Analysts expect Artivion to post earnings of $0.12 per share and revenue of $100.82 million for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

Artivion Trading Down 0.2 %

NYSE:AORT traded down $0.06 during trading hours on Friday, hitting $30.08. 141,682 shares of the stock were exchanged, compared to its average volume of 342,828. The company's 50 day moving average is $29.78 and its two-hundred day moving average is $27.68. Artivion has a twelve month low of $17.40 and a twelve month high of $32.33. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $1.26 billion, a P/E ratio of -1,503.95 and a beta of 1.75.

Analysts Set New Price Targets

Several analysts have commented on the stock. Oppenheimer upped their target price on shares of Artivion from $30.00 to $32.00 and gave the company an "outperform" rating in a research report on Friday, November 8th. Needham & Company LLC reiterated a "buy" rating and set a $34.00 target price on shares of Artivion in a research report on Tuesday, January 28th. Finally, JMP Securities reiterated a "market outperform" rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $31.80.

Insider Activity at Artivion

In other Artivion news, CAO Amy Horton sold 4,329 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the transaction, the chief accounting officer now owns 135,660 shares in the company, valued at approximately $4,023,675.60. This represents a 3.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jean F. Holloway sold 8,070 shares of the stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total value of $243,068.40. Following the transaction, the senior vice president now owns 153,862 shares of the company's stock, valued at approximately $4,634,323.44. This trade represents a 4.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,017 shares of company stock worth $600,007 in the last quarter. Corporate insiders own 8.10% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.